Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

The study aims is to evaluate the efficacy and tolerability of L-Carnitine on biomarkers of myocardial reperfusion injury in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI by the assessment of nitrotyrosine as an oxidative stress marker and Matrix metallopeptidase-2 (MMP-2) as a cardiac fibrosis marker

Start Date01 Oct 2024

Sponsor / Collaborator

Ain Shams University

IRCT20191104045328N27 / RecruitingPhase 3IIT

The effect of L-carnitine in improving the nutritional status and dialysis adequacy of hemodialysis patients in Hami dialysis center Arak city.

Start Date12 Sep 2024

Sponsor / Collaborator

Arak University of Medical Sciences

100 Clinical Results associated with Levocarnitine

100 Translational Medicine associated with Levocarnitine

100 Patents (Medical) associated with Levocarnitine

8,359

Literatures (Medical) associated with Levocarnitine

01 Jan 2025·Progress in Neuro-Psychopharmacology and Biological Psychiatry

The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part II: The future

Review

Author: Mirabelli, Silvestro ; Cortese, Samuele ; Parlatini, Valeria ; Persico, Antonio M. ; Asta, Lisa ; Arango, Celso ; Chehbani, Fethia ; Vitiello, Benedetto ; Persico, Antonio M

Part I of this systematic review summarized the state-of-the-art of pediatric psychopharmacology for Autism Spectrum Disorder (ASD), a severe and lifelong neurodevelopmental disorder. The purpose of this Part II follow-up article is to provide a systematic overview of the experimental psychopharmacology of ASD. To this aim, we have first identified in the Clinicaltrials.gov website all the 157 pharmacological and nutraceutical compounds which have been experimentally tested in children and adolescents with ASD using the randomized placebo-controlled trial (RCT) design. After excluding 24 drugs already presented in Part I, a systematic review spanning each of the remaining 133 compounds was registered on Prospero (ID: CRD42023476555), performed on PubMed (August 8, 2024), and completed with EBSCO, PsycINFO (psychology and psychiatry literature) and the Cochrane Database of Systematic reviews, yielding a total of 115 published RCTs, including 57 trials for 23 pharmacological compounds and 48 trials for 17 nutraceuticals/supplements. Melatonin and oxytocin were not included, because recent systematic reviews have been already published for both these compounds. RCTs of drugs with the strongest foundation in preclinical research, namely arbaclofen, balovaptan and bumetanide have all failed to reach their primary end-points, although efforts to target specific patient subgroups do warrant further investigation. For the vast majority of compounds, including cannabidiol, vasopressin, and probiotics, insufficient evidence of efficacy and safety is available. However, a small subset of compounds, including N-acetylcysteine, folinic acid, l-carnitine, coenzyme Q10, sulforaphane, and metformin may already be considered, with due caution, for clinical use, because there is promising evidence of efficacy and a high safety profile. For several other compounds, such as secretin, efficacy can be confidently excluded, and/or the data discourage undertaking new RCTs. Part I and Part II summarize "drug-based" information, which will be ultimately merged to provide clinicians with a "symptom-based" consensus statement in a conclusive Part III, with the overarching aim to foster evidence-based clinical practices and to organize new strategies for future clinical trials.

01 Jan 2025·Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology

Effects of water immersion on immune, intestinal flora and metabolome of Chinese mitten crab (Eriocheir sinensis) after air exposure

Article

Author: Wang, Shihui ; Zhao, Zhigang ; Deng, Xiangyi ; Li, Zhiqiang ; Yang, Yuhong ; Luo, Liang ; Zhang, Rui ; Guo, Kun ; Qiao, Guo

Air exposure stress can induce stress response of Eriocheir sinensis and affect its normal life activities. The goal of this study was to investigate the effects of water immersion on the recovery of hepatopancreas immune-related enzyme activity, intestinal microbial diversity and metabolic level of Chinese mitten crabs after exposure to air. The results show that immersion can effectively alleviate the adverse effects of air exposure on the antioxidant capacity and immune capacity of Chinese mitten crabs, and the longer the time of immersion, the more obvious the recovery effect. Among them, the levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and acid phosphatase significantly increased after exposure to air (P < 0.05), reached a peak at 3 h, began to decline after immersion, and returned to a level close to the initial value at 24 h (P < 0.05). In addition, after exposure to air, the glucose and total cholesterol in haemolymph of Eriocheir sinensis were significantly different from the initial values (P < 0.05), gradually recovered to the initial level after re-immersion. However, changes in intestinal flora and hepatopancreas metabolism caused by air exposure did not fully recover after water exposure, and its negative effects did not completely disappear. The sequencing results showed that the species composition and diversity of intestinal microorganisms of Chinese mitten crab changed after air exposure and immersion treatment. The relative abundance of Actinomycetes increased significantly, while that of Proteobacteria and Firmicutes decreased significantly. Metabolomics analysis showed that air exposure and immersion destroyed the metabolic balance of amino acids and carnitine, reduced the level of carnitine metabolism, hindered the absorption of nutrients, and led to the accumulation of harmful substances.

31 Dec 2024·Gynecological Endocrinology

Statement of Retraction: Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

News (Medical) associated with Levocarnitine

12 Nov 2024

·www.prnewswire.com

2024 Tsingke High-Impact Literature Compilation - Gene Synthesis

BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke has delivered high-quality biotechnology services and products to nearly 300,000 users globally. The number of high-level academic papers published using Tsingke's products and services has grown steadily year after year, continuously driving the advancement of life science research. We have selected two high-impact papers, published in prestigious journals, spanning a range of fields from gene function research to immunotherapy. Compilation of High-Impact Literature 1. Title: Enhancing rice panicle branching and grain yield through tissue-specific brassinosteroid inhibition DOI: 10.1126/science.adk8838 Journal: Science Impact Factor: 56.9 Summary: This study shows that crop yield potential is limited by inherent trade-offs between grain size and number. While brassinosteroids (BRs) promote grain enlargement, their role in regulating grain number has been unclear. By analyzing a cluster-type rice germplasm, the researchers found that activating the BR metabolic gene BRASSINOSTEROID-DEFICIENT DWARF3 (BRD3) significantly increases grain number. A molecular pathway was established where the BR signal inhibitor GSK3/SHAGGY-LIKE KINASE2 phosphorylates and stabilizes the OsMADS1 transcription factor, which targets the TERMINAL FLOWER1-like gene RICE CENTRORADIALIS2. Tissue-specific activation of BRD3 in secondary branch meristems enhances panicle branching, reduces the negative impact on grain size, and improves grain yield. The study demonstrates the powerful role of tissue-specific hormone manipulation in overcoming trait trade-offs and unlocking rice yield potential. 2. Title: Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer DOI: 10.1038/s41392-024-01772-w Journal: Signal Transduction and Targeted Therapy Impact Factor: 39.3 Summary: Despite the success of immune checkpoint therapies, resistance and relapse remain common in lung cancer. Cancer stem cells (CSCs) are an important factor in immune therapy resistance. Ferroptosis, a form of cell death driven by iron-dependent lipid peroxidation, has shown synergistic effects with immunotherapy. This study shows that the key rate-limiting enzyme CPT1A in fatty acid oxidation, together with L-carnitine from tumor-associated macrophages, drives ferroptosis resistance and CD8+ T cell dysfunction in lung cancer. Mechanistically, CPT1A inhibits the ubiquitination and degradation of c-Myc, which transcriptionally activates CPT1A expression. The CPT1A/c-Myc positive feedback loop enhances the NRF2/GPX4 system and reduces the quantity of phospholipid polyunsaturated fatty acids, boosting cellular antioxidant capacity and suppressing ferroptosis in CSCs. Importantly, targeting CPT1A enhances anti-tumor immunity and ferroptosis in immune checkpoint blockade therapy in tumor-bearing mice. These results present a metabolic vulnerability-targeting approach to improve lung cancer immunotherapy efficacy. Tsynth™ Gene Synthesis Tsingke is built on a foundation of advanced gene synthesis technology, supported by a gene-smart molecular splitting and assembly platform that enhances accuracy and success rates. Leveraging years of expertise in life sciences, bioinformatics, and computer science, Tsingke has pioneered cutting-edge codon optimization techniques. At the same time, the company utilizes the propeller system (TSINGKE HELIXTECH), an integrated full-cycle management system that combines customer service, production management, and lean management. By employing AI algorithms, it effectively links raw materials, equipment, and processes, powering intelligent production lines and precise gene detection quality control techniques. This enables Tsingke to provide low-cost, high-efficiency, and high-quality gene synthesis services, meeting the needs of researchers in fields such as life science research, biopharmaceuticals, biological breeding, biomanufacturing, and gene storage. For more high-impact papers utilizing Tsingke's products and services, visit our website to explore how our solutions are helping advance research worldwide. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyGene Therapy

28 Oct 2024

·www.prnewswire.com

Cocrystal Health Industry Announces Launch of Best in Class Bioabsorption and Stability Cocrystallized Lutein and Curcumin Technologies

Patented and clinically verified nutraceutical actives outperform current branded offerings and offer a powerful solution for supplement product potency concerns. LAS VEGAS, Oct. 28, 2024 /PRNewswire/ -- At the Supplyside West tradeshow this week representatives from Cocrystal Health Industry are announcing the launch of the Cocrystal Lutein and Curcumin powder actives. Backed by 60 global patents and near 100 published papers, the company leverages their proprietary and clean cocrystallization platform to produce actives with dramatically improved bioabsorption, stability and functionality relative to existing offerings. These launches build on their existing cocrystallized ingredient portfolio which includes Ubiquinol CoQ10, Hydroxytyrosol and Alpha Tocopherol Vitamin E. Continue Reading Cocrystal Curcumin Powder Cocrystal Lutein Powder Lutein is well demonstrated in clinical research to support eye health, though traditional lutein ingredients have poor bioabsorption, solubility, and stability, as the ingredient is easily oxidized. Powered by Cocrystal Health Industry's clean, vegan and non-GMO cocrystallization process, Cocrystal Lutein now provides a powerful solution to address these concerns. In 3rd party testing, Cocrystal Lutein demonstrated over 6 times greater bioabsorption and 3 times better solubility compared to current marketed lutein. In a head-to-head capsule stability study, the cocrystal advantage is even more dramatic. Cocrystal Lutein maintained over 99% of potency in capsules after 30 days, while current marketed lutein maintained less than 2% of its original potency. In addition to performance advantages, the cocrystal technology offers a significant cost savings relative to well known branded lutein. While well researched to support a range of benefits including joint and cognitive health, marketed curcumin extracts are similarly limited by very poor bioavailability. Patented Cocrystal Curcumin featuring L-Carnitine as a ligand has been shown in studies to offer over 10X greater bioabsorption in comparison to current marketed curcumin. And while there are several enhanced bioavailability curcumin materials available, in a head-to-head study Cocrystal Curcumin showed significantly better bioabsorption even relative to an existing enhanced offer. Alex Mei, PhD, Cocrystal Health Industry's Founder & CEO commented, "We are thrilled to expand our portfolio and introduce powerful new solutions in our Cocrystal Lutein & Curcumin technologies. Our proprietary platform solves for multiple nutrition brand concerns – providing meaningful differentiation and unparalleled benefit performance to their consumers, while ensuring sustained potency against label claim. As the global leader in cocrystallized active ingredients, we're proud to offer these transformative solutions." To learn more manufacturers and formulators can reach out to [email protected]. About Cocrystal Health Industry: Backed by 60 global patents and near 100 published papers, Cocrystal Health Industry introduces cocrystal powder technologies as unprecedented solutions for poor stability and low bioavailability ingredients. With demonstrated best in class bioavailability and superior in-formula stability, our actives also feature pure nature integrity, improved solubility, dissolution, melting point and flowability versus existing offerings. Beyond their superior performance, Cocrystal actives typically offer a cost advantage relative to other branded ingredients. The company's growing portfolio includes Cocrystal Ubiquinol, Hydroxytyrosol, Alpha Tocopherol, Rutin and now Lutein and Curcumin. For more information visit . Media Contact: Jeff Avila 305-632-1733 [email protected] SOURCE Cocrystal Health Industry WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

16 Oct 2023

·www.prnewswire.com

Native Pet Expands Its Growing Portfolio with the Launch of The Daily, An All-In-One Premium Supplement

An everyday product formulated to enhance your dog's daily diet and make a real difference in their health ST. LOUIS, Oct. 16, 2023 /PRNewswire/ -- Native Pet, a leading pet supplement company, announced today the addition of its most powerful and advanced product yet, The Daily. Continuing to challenge the industry, the launch of The Daily lives up to The Native Pet Pact, the brand's unwavering commitment to making a real difference in your pets' health. After two years of development, The Daily comes to market offering a science-backed, everyday solution for your dog's well-being using only the highest-quality and most efficacious ingredients. Continue Reading An everyday product formulated to enhance your dog’s daily diet and make a real difference in their health. "After years of research and development, we're thrilled to introduce The Daily," said Dan Schaefer, CEO and co-founder of Native Pet. "This all-in-one supplement is the first of its kind, packing all the powerful ingredients your dog needs into one tasty and science-backed scoop. Since we know kibble only goes so far, we created The Daily to fit seamlessly into your pet's daily routine and support them through all phases of their tail-wagging lives." Offering a solution for a category composed of mostly soft chews, The Daily's unique powder format ensures the integrity of the active ingredients and the highest level of efficacy for dogs. The new super supplement was formulated with the cleanest label possible, providing real, whole-food ingredients, zero additives or fillers, and the highest number of active ingredients on the market. Pat Barron, Native Pet COO and co-founder added, "We worked hand-in-hand with a team of vet nutritionists, veterinarians, and food scientists, and we're proud to introduce this everyday wellness supplement to support the most common ailments in canine health. We are committed to formulating only the very best products for our pets, which means developing proprietary formulas and hand-selecting ingredients." Barron further explains, "When formulating The Daily, we tapped into powerful active ingredients with Probiotics, L-Carnitine, and Zinc along with more familiar ingredients like Goat Milk, Bone Broth, and Pumpkin to ensure we're making the greatest impact for canine health and wellness." With 11 benefits in just one tasty scoop, The Daily's powerful blend of ingredients work together to support energy utilization, skin and coat health, mobility, gut health, and beyond. The launch of The Daily not only marks an exciting milestone for the brand portfolio, but also solidifies the demand for wider accessibility to Native Pet's products. The brand can now be found in nearly 2,000 retail locations, including 600 Target stores and over 1,000 Petco Pet Care Centers nationwide. Native Pet's continued partnership with Target and expansion into Petco further cements the brand as a leader in the growing market category and supports pet parents everywhere in prioritizing their dogs' health. The Daily is now available online at nativepet.com, Chewy, Amazon, and select Target stores. For more information, visit nativepet.com or follow @nativepet on Instagram and TikTok. About Native Pet Native Pet is committed to developing proprietary formulas and formats, offering only the best, most innovative supplements to directly benefit the health of pets. In an industry that has never prioritized the health of our pets, Native Pet is redefining the bar and holds true to its motto that "we're the voice of our pets and it's our mission to give our fur babies the best lives. Because our love language is dog, and dog is our native tongue." Media Contact [email protected] SOURCE Native Pet

100 Deals associated with Levocarnitine

External Link

KEGG	Wiki	ATC	Drug Bank
D02176	Levocarnitine	A16AA01	DB00583

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Kidney Diseases	IT	Alfasigma SpA	18 May 2015
Shock, Septic	IT	Alfasigma SpA	18 May 2015
Cardiovascular Diseases	CN	Leadiant Biosciences, Inc.	31 Dec 1999
Metabolism, Inborn Errors	IE	Shire Pharmaceutical Development Ltd.	23 Oct 1996
Carnitine palmitoyltransferase deficiency	NL	Sigma-Tau Industrie Farmaceutiche Riunite SpA	03 Feb 1986
Systemic Carnitine Deficiency	US	Leadiant Biosciences, Inc.	27 Dec 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Phase 3	EG	Tanta University	05 Mar 2023
Pain	Phase 3	EG	Tanta University	05 Mar 2023
Rheumatoid Arthritis	Phase 3	EG	Tanta University	05 Mar 2023
Heart Failure	Phase 1	CN	Lee's Pharmaceutical Holdings Ltd.	01 Jan 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AASLD2023	Not Applicable	Hepatic Encephalopathy \| Hyperammonemia	-	Oral L-Carnitine	okbuszrvdg(vgvhduoesk) = fgzdoisxco scdorolwvl (mwrgouwama ) View more	-	10 Nov 2023
ESMO2022	Not Applicable	Head and Neck Neoplasms	150	L-carnitine 500mg	(pbdrgbzlyu) = lacamizgsn carvwchwjd (faliiisakw )	-	10 Sep 2022
				L-carnitine (Control)	(pbdrgbzlyu) = qfqseunbad carvwchwjd (faliiisakw )
NCT01783041 (CTgov)	Phase 2/3	Systemic Carnitine Deficiency \| Obstetric Labor, Premature \| Neurodevelopmental Disorders	144	5% dextrose (5% Dextrose)	skolkevdfx(uohqoiecwo) = ogqsjxichg gepmxrkufr (uqwctgulqz, tqeyzxitwj - nsipxbnkqc) View more	-	08 Mar 2022
				L-carnitine (L-carnitine)	skolkevdfx(uohqoiecwo) = bhxbqihvdy gepmxrkufr (uqwctgulqz, pukuqxhohh - yxnszlrfak) View more
ESC2021	Not Applicable	Burns, Electric KCNH2-N588K	-	L-Carnitine	(xbibkerbcs) = soavafvvyi feaduvtwax (xxyjnvlocg ) View more	-	29 Aug 2021
				L-Carnitine	(xbibkerbcs) = specbkoruz feaduvtwax (xxyjnvlocg )
MO641 (ERA2021)	Not Applicable	Kidney Failure, Chronic	48	Magnesium aspartate + L-carnitine	kdcefaxbwm(vfwvekxrfn) = mbdnkbtzha exgpgpicam (vowmtnaskd )	Positive	29 May 2021
				Basic therapy	kdcefaxbwm(vfwvekxrfn) = zytocyhjml exgpgpicam (vowmtnaskd )
ASN2019	Not Applicable	Peritoneal dialysis complication serum free carnitine (FC) \| acyl-carnitine (AC) \| urinary L-FABP ... View more	24	L-carnitine supplementation (750 mg/day)	njuytbbyku(qipljclwgx) = hfsyfzhany jsmttnjhgh (edmldgslmq ) View more	Positive	05 Nov 2019
				L-Carnitine	njuytbbyku(qipljclwgx) = wowgtxwnld jsmttnjhgh (edmldgslmq ) View more
UEGW	Not Applicable	Liver Cirrhosis	46	Levocarnitine < 1500 mg/day	dnfqetvqwt(bbajmctmjl) = jpklcyikrq kgxmpdmchy (glbusmgfhq, 52)	Positive	01 Oct 2019
				Levocarnitine 1500 mg/day or more	dnfqetvqwt(bbajmctmjl) = ullbqmugar kgxmpdmchy (glbusmgfhq, 124)
NCT01665092 (RACE, CTgov)	Phase 2	Shock, Septic	250	placebo (Control)	nzlywjypnx(qscbtanzly) = itmtcnkxsd menerpbnan (zyikwanneu, ztgubgdolx - zdlihegdoy) View more	-	04 Jun 2019
				Levo-Carnitine (Carnitine Low)	nzlywjypnx(qscbtanzly) = ublehqbodb menerpbnan (zyikwanneu, wxxjhykciq - gbvrbxnvme) View more
NCT01665092 (RACE, Pubmed \| JAMA Netw Open)	Phase 2	Shock, Septic	250	Levocarnitine 18g	(qfhopedcvf) = bltshcxtla orqagrdnsy (qrrlzwvoza )	Negative	07 Dec 2018
				Placebo	(qfhopedcvf) = aeavarwcgu orqagrdnsy (qrrlzwvoza )
Pubmed \| J Clin Endocrinol Metab	Not Applicable	Systemic Carnitine Deficiency	-	Patients with PCD with l-carnitine treatment	pmpkwgijvg(ixbxwlrrmf) = clhbwranjl hgzkaayidr (booewskrvk )	-	01 Dec 2018
				Patients with PCD without l-carnitine treatment	pmpkwgijvg(ixbxwlrrmf) = ppmbpommhj hgzkaayidr (booewskrvk )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis